Acoltremon Combination Eye Drops for Tear Film Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dry eye and dysfunctional tear syndrome are inadequate in effectively addressing the signs and symptoms, and there is a need for improved therapeutic options that can stabilize the tear film and reduce inflammation.
Innovation Solution
Combinations of acoltremon with lifitegrast or cyclosporin, optionally including semifluorinated alkanes, are administered topically to enhance tear film stability and reduce inflammation, acting synergistically to improve dry eye symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monotherapies are used to address dry eye, then treatment is simpler, but therapeutic effectiveness is insufficient
Solution Approach 1:
The patent combines multiple active pharmaceutical agents (acoltremon with lifitegrast or cyclosporin) into a single ocular instillation solution, merging the therapeutic effects of individual monotherapies into a unified treatment that addresses multiple aspects of dry eye pathology simultaneously, thereby improving overall therapeutic effectiveness
2Reliability
If combination therapy is used to improve therapeutic effectiveness, then treatment complexity increases
Solution Approach 1:
Multiple active pharmaceutical agents are combined into a single ocular instillation solution, allowing combination therapy to be administered as one unified treatment rather than multiple separate applications, thereby maintaining improved therapeutic effectiveness while reducing treatment complexity
3Stability of the object's composition
If combination of acoltremon with lifitegrast or cyclosporin is used, then tear film stability is improved, but formulation complexity increases
Solution Approach 1:
The patent creates a composite pharmaceutical formulation containing acoltremon combined with lifitegrast or cyclosporin in a single ocular instillation solution, leveraging the complementary mechanisms of action of different agents to stabilize the tear film while managing formulation complexity through integrated design
Data Source
AI summary
Provided herein are combinations comprising: 1) acoltremon; and 2) lifitegrast or cyclosporin, or a pharmaceutically acceptable salt thereof. The combinations are useful for treating dry eye or dysfunctional tear syndrome, or a sign or symptom thereof.